证券代码：603599 证券简称：广信股份 公告编号：2023-034 安徽广信农化股份有限公司 关于为全资及控股子公司申请授信提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 被担保人名称：安徽东至广信农化有限公司、辽宁世星药化有限公司 本次担保金额：本次为安徽东至广信农化有限公司提供的担保金额不超 过 10,000 万元，已实际为其提供的担保余额：0 万元； 本次为辽宁世星药化有限公司提供的担保金额不超过 12,000 万元，已 实际为其提供的担保余额：0 万元； 本次担保是否有反担保:否； 公司无逾期的对外担保。 一、担保情况概述 （一）担保基本情况 1、因经营发展需要，安徽东至广信农化有限公司向工商银行股份有限公司 东至支行申请综合授信不超过人民币 10,000 万元，授信期限一年，由安徽广信 农化股份有限公司（以下简称"公司"）提供最高额连带责任保证担保。 （二）本担保事项履行的内部决策程序。 上述担保事项已经公司第五届董事会第十二次会议审议通过。 二、被担保人基本情况 （一）公司 ...

证券代码：603599 证券简称：广信股份 公告编号：2023-027 安徽广信农化股份有限公司 关于子公司 4 万吨对氨基苯酚项目投产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏并对其内容的真实性、准确性和完整性承担个别及连带责任。 安徽广信农化股份有限公司（以下简称"公司"）全资子公司安徽东至广信 农化有限公司"年产 4 万吨对氨基苯酚项目" 经过前期生产工艺、机器设备的 安装调试，已于近期正式全面投产。项目建成后，进一步夯实公司产业链条，延 伸了氯碱-对（邻）硝基氯化苯等上下游原材料的应用，提升主业竞争力，正式 打通了从光气–精细化工品-医药中间体的链条板块，构筑产业链共生生态，实 现价值升级。 公司"年产 4 万吨对氨基苯酚项目"是经公司第五届董事会第六次会议及 2021 年年度股东大会审议通过，由公司非公开发行募投项目"广信股份 3,000 吨/年吡唑醚菌酯项目" 变更而来，项目总投资 41,254.90 万元。具体信息请 详见公司于 2022 年 4 月 28 日刊登在上海证券交易所网站及指定媒体的公告。 项目建成后，项目所需的水、电、蒸汽等，均依托公司 ...

Revenue and Profitability - The company's revenue from pesticides reached ¥9,062,370,119.54, with a gross margin of 40.99%, reflecting a year-over-year revenue increase of 63.29%[4] - Revenue from pesticides was ¥5,658,556,112.00, with a gross margin of 42.30%, showing a 68.38% increase in revenue compared to the previous year[4] - Domestic revenue amounted to ¥6,902,689,973.38, with a gross margin of 43.03%, representing a 63.49% increase year-over-year[4] - The total revenue for 2022 reached ¥1,359,845,784.87, a significant increase from ¥673,103,585.92 in 2021, representing a growth of approximately 102%[78] - The net profit for 2022 was ¥1,180,368,854.23, compared to ¥591,868,394.88 in 2021, indicating an increase of about 99%[78] - The comprehensive income for the year amounted to approximately RMB 1.48 billion[37] - The total comprehensive income for 2022 was ¥1,180,368,854.23, compared to ¥591,868,394.88 in 2021, marking a growth of approximately 99%[78] Production and Capacity - The production volume of pesticides and intermediates was 310,432.51 tons, with a sales volume of 303,657.16 tons, indicating a 72.26% increase in sales compared to the previous year[5] - A new production line with a capacity of 100,000 tons/year for ortho-nitrochlorobenzene was successfully put into operation, strengthening the company's position in the pesticide industry[52] - The company has a designed capacity of 36.3 million tons per year for its main pesticides and intermediates, with a capacity utilization rate of 85.51%[135] - The company is currently constructing an additional capacity of 40,000 tons per year for aminophenol, with an investment of approximately RMB 32,953.47 million, expected to be completed in 2023[135] Research and Development - The company has established a research and development center with a team of 359 personnel, accounting for 13.82% of the total workforce[27] - The company has developed and mastered multiple production technologies, including DAP/HAP impurity control technology and thiocyanate reaction technology, holding several patents[21] - The company aims to enhance its technological capabilities through ongoing research and development initiatives[78] - The company has implemented advanced synthesis techniques in its production processes, significantly improving product quality and reducing harmful impurities[128] Market Position and Strategy - The company plans to expand its product offerings and improve supply chain capabilities to strengthen its market position[15] - The company aims to enhance its market presence in the agricultural chemicals sector, focusing on sustainable development and high-efficiency low-toxicity products[73] - The company aims to expand its global business footprint by exploring overseas markets and increasing global registration investments[52] - The company has established long-term stable partnerships with renowned clients such as DuPont and FMC, which supports continuous business growth[22] Financial Performance and Investments - The total cash received from sales of goods and services in 2022 was approximately RMB 5.33 billion, compared to RMB 3.14 billion in 2021, indicating a significant increase[32] - Cash flow from operating activities for 2022 was ¥2,927,988,016.26, up from ¥1,410,612,292.25 in 2021, reflecting an increase of approximately 107%[83] - The company reported cash and cash equivalents at the end of 2022 amounting to ¥2,893,073,050.29, an increase from ¥2,259,071,354.55 at the end of 2021, which is a growth of about 28%[85] - The company reported a significant increase in profitability due to strong domestic and international market demand and rising raw material prices[58] Acquisitions and Partnerships - The company acquired a 70% stake in Liaoning Shixing Pharmaceutical Chemical Co., Ltd. for ¥210 million, completed on June 1, 2022[12] - The company completed the acquisition of its subsidiary, Liaoning Shixing Pharmaceutical, enhancing its integrated strategy and diversifying its product structure[52] - Future acquisitions and mergers will be considered to enrich the product line and enhance market share[192] Supply Chain and Procurement - The company has a procurement strategy that focuses on order-driven purchasing to mitigate raw material price fluctuations, with key suppliers located in several provinces[119] - The company has a rigorous supplier qualification process, ensuring that new suppliers meet quality and capability standards before being approved[120] Regulatory and Compliance - The company’s financial statements comply with accounting standards, reflecting its financial position and operating results accurately[149] - The company’s consolidated financial statements reflect the overall financial status and cash flows of the entire corporate group[164] Talent and Human Resources - The company emphasizes the importance of attracting and retaining talent to drive its development[190] - The company has a strong focus on technological innovation, with a dedicated committee led by the chairman to oversee development and innovation efforts[125]

Financial Performance - The net profit attributable to shareholders of the listed company was CNY 521,213,182.36, representing a decrease of 8.43% year-on-year[19]. - The operating revenue for Q1 2023 was CNY 1,925,991,278.96, down 6.35% from the same period last year[19]. - Basic and diluted earnings per share were both CNY 0.80, down 8.94% year-on-year[19]. - Total operating revenue for Q1 2023 was CNY 1,925,991,278.96, a decrease of 6.34% compared to CNY 2,056,692,232.95 in Q1 2022[42]. - Total operating costs for Q1 2023 were CNY 1,385,356,252.05, down 2.55% from CNY 1,421,754,830.52 in Q1 2022[42]. - The total revenue for the first quarter of 2023 was approximately CNY 1,351.19 million, a decrease from CNY 1,434.89 million in the same period of 2022, representing a decline of about 5.8%[34]. Cash Flow - The net cash flow from operating activities was CNY 161,186,254.65, a significant decline of 78.41% compared to the previous year[19]. - The net cash flow from operating activities for the first quarter of 2023 was CNY 161.19 million, significantly lower than CNY 746.43 million in the first quarter of 2022, indicating a decrease of approximately 78.5%[34]. - The cash inflow from investment activities was CNY 1,704.47 million in the first quarter of 2023, compared to CNY 1,974.45 million in the same period of 2022, reflecting a decline of about 13.7%[34]. - The cash received from the recovery of investments was CNY 1,680 million in the first quarter of 2023, compared to CNY 1,955.76 million in the same period of 2022, reflecting a decrease of approximately 14%[34]. - Net cash flow from investing activities for Q1 2023 was CNY 461,903,204.58, compared to a negative cash flow of CNY -654,422,808.93 in Q1 2022[35]. - Net cash flow from financing activities for Q1 2023 was CNY 127,808,052.84, a decrease from CNY 186,231,655.37 in Q1 2022[35]. - The net increase in cash and cash equivalents for Q1 2023 was CNY 729,531,472.38, compared to CNY 282,174,798.71 in Q1 2022, showing a significant improvement[35]. Assets and Liabilities - In Q1 2023, the company's total assets decreased by 0.94% to CNY 13,720,672,855.10 compared to the end of the previous year[5]. - The total liabilities as of the end of Q1 2023 amounted to CNY 4,359,977,532.14, down from CNY 5,036,599,874.69 at the end of Q1 2022[40]. - The company's equity attributable to shareholders increased by 6.14% to CNY 9,211,002,489.52 compared to the end of the previous year[5]. - The total equity attributable to shareholders was CNY 9,211,002,489.52 in Q1 2023, compared to CNY 8,678,212,706.53 in Q1 2022, reflecting an increase of 6.12%[40]. - Accounts receivable increased by 31.80% due to an increase in sales not yet collected[49]. - Other receivables rose by 38.96% primarily due to the transfer of some prepaid amounts to other receivables[49]. - Short-term borrowings rose from $1.24 billion to $1.37 billion, an increase of approximately 10.5%[53]. - Accounts payable decreased from $1.64 billion to $1.40 billion, a decline of about 14.8%[53]. - Contract liabilities decreased significantly from $437.72 million to $215.38 million, a reduction of approximately 50.8%[53]. - Deferred tax assets decreased from $87.92 million to $75.47 million, a decline of about 14.1%[53]. - The company reported a total non-current liability of $3.51 billion, reflecting a stable financial position[53]. Expenses and Other Income - The financial expenses increased by CNY 114.44 million due to exchange losses from the depreciation of the US dollar against the RMB[8]. - The company reported a fair value change gain of CNY 303.68 million, primarily due to increased investment income from financial products[8]. - Non-recurring gains and losses included CNY 39,332,107.48 from unrelated business activities[21]. - The company reported a total of CNY 296.57 million in other non-operating income and expenses during the reporting period[22]. - The income tax expense for the period was CNY 7.66 million, and the impact on minority interests (after tax) was CNY 625.77 million[22]. Research and Development - Research and development expenses for Q1 2023 were CNY 75,466,202.67, down from CNY 89,267,582.42 in Q1 2022, indicating a reduction of 15.5%[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,688, with the largest shareholder, Anhui Guangxin Group Co., Ltd., holding 40.58% of the shares[25]. Company Strategy - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[34].

证券代码：603599 证券简称：广信股份 公告编号：2023-015 安徽广信农化股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 任。 重要内容提示： 会议召开时间：2023 年 04 月 28 日(星期五) 上午 11:00- 12:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 25 日(星期二) 至 04 月 27 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 guangxinzq@chinaguangxin.com 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 安徽广信农化股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年度报告，为便于广大投资者更全面深入 地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 ...

2022 年第三季度报告 单位：元 币种：人民币 1 / 13 证券代码：603599 证券简称：广信股份 安徽广信农化股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------------|-----------------------------------------|------------------------|---------- ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders reached 200 million RMB, up 10% compared to the same period last year[21]. - Revenue for the reporting period (January to June) reached ¥4,502,529,254.63, an increase of 79.44% compared to the same period last year[23]. - Net profit attributable to shareholders was ¥1,243,285,943.89, reflecting a growth of 97.23% year-over-year[23]. - Net profit excluding non-recurring gains and losses increased by 102.89% to ¥1,173,722,902.87 compared to the previous year[23]. - Net cash flow from operating activities rose by 101.07% to ¥1,463,658,939.21, driven by increased sales and profit[23]. - Basic earnings per share increased by 96.91% to ¥1.91, attributed to significant growth in revenue and profit[23]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2022, representing a 15% year-over-year growth[100]. - The net profit for the first half of 2022 was CNY 1,264,581,029.93, representing a 100.8% increase from CNY 630,360,928.70 in the same period of 2021[179]. - The total comprehensive income for the first half of 2022 was CNY 1,264,581,029.93, compared to CNY 630,360,928.70 in the same period of 2021, indicating a growth of 100.8%[179]. User Growth and Market Expansion - The company expanded its user base by 25%, reaching a total of 500,000 active users in the reporting period[21]. - User data indicates a growth in active users, reaching 5 million, which is a 20% increase compared to the previous year[100]. - The company plans to launch two new products in Q3 2022, aiming to capture an additional 5% market share[21]. - The company plans to expand its market presence by entering three new provinces in China by the end of 2022, aiming for a 25% increase in market share[100]. - A strategic acquisition of a local competitor is in progress, which is anticipated to increase the company's customer base by 15%[100]. Research and Development - Research and development expenses increased by 20%, totaling 50 million RMB, focusing on new pesticide formulations[21]. - Research and development expenses increased by 58.83% to CNY 219,458,089.11, indicating a strong commitment to innovation[45]. - The company has committed to investing 100 million CNY in research and development for innovative product lines over the next two years[100]. Financial Guidance and Projections - The management provided a revenue guidance of 2.5 billion RMB for the full year 2022, indicating a growth target of 12%[21]. - The company has set a future outlook with a revenue target of 2.5 billion CNY for the full year 2022, indicating a projected growth of 10%[100]. Risk Management - The company has identified key risks including raw material price fluctuations and regulatory changes in the agricultural sector[21]. - The company faces risks related to safety and environmental regulations, particularly in the chemical industry[59]. - Raw material costs account for 82% of production costs, making the company vulnerable to price fluctuations in key raw materials[60]. Environmental Compliance and Initiatives - The company has implemented pollution control facilities, ensuring stable and compliant emissions from its operations[77]. - The company achieved wastewater discharge compliance with standards, including CODcr levels of 9.9957 mg/L and ammonia nitrogen levels of 1.0344 mg/L[72]. - The company has committed to energy management and carbon emission reduction, establishing an energy management office to improve energy efficiency[87]. - The company has reported no administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[84]. - The company has actively promoted environmental protection measures, focusing on reducing emissions of waste and pollutants, and has successfully implemented multiple modification projects[86]. Corporate Governance and Shareholder Information - The company reported no significant non-operational fund occupation by controlling shareholders during the reporting period[21]. - The company reported no significant legal disputes or regulatory penalties during the reporting period, reflecting a stable operational environment[100]. - The board of directors is actively monitoring the implementation of corporate governance practices to ensure transparency and accountability[100]. - The number of ordinary shareholders at the end of the reporting period is 16,137[147]. - The largest shareholder, Anhui Guangxin Group Co., Ltd., holds 263,843,504 shares, accounting for 40.57% of the total shares[147]. Asset and Liability Management - Total assets grew by 41.17% to ¥11,497,461,797.69 compared to the end of the previous year[23]. - The total liabilities amounted to CNY 5,194,660,908.78, an increase of 11.8% from CNY 4,647,563,392.83 in the previous year[178]. - Owner's equity increased to ¥7,855,335,078.09 from ¥6,959,116,281.47, showing an increase of about 12.8%[166].

Financial Performance - The company's operating revenue for Q1 2022 was ¥2,056,692,232.95, representing a 64.39% increase compared to the same period last year [6] - Net profit attributable to shareholders was ¥569,169,538.35, reflecting a 101.90% year-over-year growth [6] - Basic earnings per share (EPS) was ¥1.23, up by 101.64% year-over-year [6] - Operating profit for Q1 2022 was ¥672,936,873.02, up 108.5% from ¥322,885,938.38 in Q1 2021 [30] - Net profit attributable to shareholders for Q1 2022 was ¥569,169,538.35, representing a 102.1% increase from ¥281,903,176.13 in Q1 2021 [32] - Total equity attributable to shareholders rose to ¥7,544,804,007.72 in Q1 2022, up from ¥6,959,116,281.47 in Q1 2021, an increase of 8.4% [30] Cash Flow - The net cash flow from operating activities reached ¥746,432,072.51, a significant increase of 280.34% compared to the previous year [6] - Cash inflow from operating activities for Q1 2022 was approximately $1.48 billion, a significant increase from $910.67 million in Q1 2021, representing a growth of about 62.5% [35] - Net cash flow from operating activities reached $746.43 million in Q1 2022, compared to $196.25 million in Q1 2021, indicating a substantial increase of approximately 280.5% [35] - Cash inflow from investment activities totaled approximately $1.97 billion in Q1 2022, up from $1.66 billion in Q1 2021, reflecting an increase of about 18.7% [36] - The net increase in cash and cash equivalents for Q1 2022 was $282.17 million, contrasting with a decrease of $79.57 million in Q1 2021 [36] - The ending balance of cash and cash equivalents as of Q1 2022 was approximately $2.54 billion, compared to $1.50 billion at the end of Q1 2021, marking an increase of about 70% [36] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,400,037,517.42, an increase of 12.28% from the end of the previous year [9] - Current assets totaled RMB 8,827,531,855.26, up from RMB 7,711,881,318.96 year-over-year [21] - Total liabilities increased to ¥3,855,233,509.70 in Q1 2022 from ¥3,193,919,381.35 in Q1 2021, marking a growth of 21.0% [30] - Total current liabilities reached RMB 3,749,717,680.01, compared to RMB 3,086,094,674.41, marking an increase of approximately 21.5% [24] - Non-current assets totaled RMB 2,572,505,662.16, up from RMB 2,441,154,343.86, reflecting an increase of about 5.4% [24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,087 [16] - The largest shareholder, Anhui Guangxin Group Co., Ltd., held 40.57% of the shares [16] - The company reported a total of 188,459,646 shares held by Anhui Guangxin Group Co., Ltd., the largest shareholder [18] Research and Development - Research and development expenses rose by 73.77%, indicating increased investment in innovation [15] - Research and development expenses for Q1 2022 were ¥89,267,582.42, a 73.5% increase from ¥51,370,584.14 in Q1 2021 [30] Other Information - The company reported non-recurring gains of ¥30,792,509.18 during the quarter [12] - The company has not disclosed any significant new strategies or product developments during the reporting period [19]

Financial Performance - The company's operating revenue for 2021 reached ¥5,549,906,816.60, representing a year-on-year increase of 63.12%[22]. - The net profit attributable to shareholders for 2021 was ¥1,479,380,288.82, reflecting a significant growth of 151.28% compared to the previous year[22]. - The net cash flow from operating activities increased by 103.94% year-on-year, amounting to ¥1,410,612,292.25, primarily due to rising product prices and increased net profit[25]. - Total assets grew by 37.83% year-on-year, reaching ¥10,153,035,662.82, driven by enhanced profitability and increases in cash, investments, and inventory[25]. - Basic earnings per share for 2021 were ¥3.18, up 150.39% from the previous year, attributed to substantial growth in operating revenue and profit[25]. - The weighted average return on equity increased by 12.66 percentage points to 23.59% in 2021, indicating improved profitability[22]. - The net profit after deducting non-recurring gains and losses rose by 184.62% year-on-year to ¥1,376,145,702.21, driven by significant revenue growth[25]. - The company reported a net profit of ¥446,499,750.48 in Q4 2021, showing a steady increase throughout the year[26]. - The company experienced a net cash flow from operating activities of -¥218,166,559.40 in Q4 2021, indicating fluctuations in cash flow management[26]. Dividend and Share Capital - The company plans to distribute a cash dividend of 10 CNY per 10 shares, totaling 464,564,135 CNY, and will increase its share capital by 185,825,654 shares through a capital reserve conversion, raising total shares to 650,389,789[7]. - The company has a cash dividend policy that prioritizes cash dividends, aiming for a minimum of 30% of the average distributable profit over three consecutive years to be distributed in cash when conditions are met[166]. - The company approved a profit distribution plan for 2021, proposing a cash dividend of 10 RMB per 10 shares (including tax) and a capital reserve conversion of 4 shares for every 10 shares, totaling a cash distribution of 464,564,135 RMB and an increase in total shares to 650,389,789[171]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has outlined various risks and countermeasures in its management discussion and analysis section[8]. - The company has a comprehensive risk management strategy in place to address potential operational challenges[8]. - The company has no non-operating fund occupation by controlling shareholders or related parties[8]. - The company has no violations of decision-making procedures regarding external guarantees[8]. Audit and Compliance - The audit report issued by Rongcheng Accounting Firm confirmed the financial statements' authenticity and completeness, with a standard unqualified opinion[6]. - The company has established a strict internal control management system in compliance with regulations, ensuring legal and compliant operations and asset security[176]. - The company has disclosed its internal control audit report, which received a standard unqualified opinion[178]. - The company has not faced any penalties from securities regulatory agencies in the past three years[145]. Market and Industry Position - The global pesticide market demand remained strong in 2021 due to post-pandemic monetary easing and increased focus on food security, leading to a rise in pesticide demand[35]. - The company's sales growth was driven by the release of new production capacity, strong domestic and international market demand, and increased product prices due to rising raw material costs[41]. - The company is one of the few listed firms capable of large-scale production of ortho-nitrochlorobenzene and is a major production base for the fungicide carbendazim[40]. - The domestic pesticide industry has seen steady growth in sales and profits, with the company benefiting from the resilience of the pesticide supply chain amid global economic challenges[39]. - The company has a competitive edge in the market due to its comprehensive production system and a wide range of pesticide products[42]. Research and Development - Research and development expenses increased by 54.18% to CNY 278,518,554.68, indicating a commitment to innovation[53]. - The company has developed and mastered several production technologies, including DAP/HAP impurity control technology and thiocyanate reaction technology[48]. - The company is committed to sustainable development and improving the quality and efficiency of its operations[112]. - The company aims to enhance its research and development capabilities in response to industry trends and regulatory changes, particularly in the chemical sector[82]. - The company has invested in R&D since its establishment, with a technology center that has undertaken multiple national science and technology projects, resulting in numerous patents and recognition as a high-tech enterprise[96]. Environmental Responsibility - The company has established a wastewater treatment plant with a daily processing capacity of 5,000 tons, effectively treating high-salinity and low-salinity wastewater[188]. - The wastewater treatment process includes advanced methods such as iron-carbon micro-electrolysis and multi-effect evaporation, ensuring compliance with discharge standards[190]. - Emissions from the thermal power boiler are within regulatory limits, with sulfur dioxide at 5.803 mg/m³, nitrogen oxides at 23.772 mg/m³, and particulate matter at 0.133 mg/m³[186]. - The company has implemented comprehensive noise control measures, including the use of low-noise equipment and sound insulation techniques[189]. - The company has a robust hazardous waste management system, ensuring compliance with regulations and proper disposal of hazardous materials[193]. - The company has actively pursued green development initiatives, focusing on waste reduction and energy efficiency improvements[200]. - The company has established a carbon emission management system to promote energy efficiency and reduce greenhouse gas emissions[200]. Governance and Management - The board of directors has ensured that all members attended the board meeting, affirming the report's accuracy and completeness[5]. - The management team includes experienced professionals with backgrounds in finance, technology, and management, contributing to strategic decision-making[134]. - The board of directors is composed of individuals with diverse professional experiences, enhancing governance and oversight capabilities[136]. - The company emphasizes a people-oriented approach to human resource development, aiming to create a supportive work environment and attract talent[116]. - The company has a structured employee compensation system based on positions, with annual performance bonuses as a supplement, and provides benefits such as social insurance and paid leave[161]. Production and Operations - The company achieved a production capacity of 26.1 million tons per year with a utilization rate of 74.54%[100]. - The company has a land reserve of 4,200 acres across its two production bases, providing a strong foundation for future expansion[85]. - The company has established a complete R&D, procurement, production, testing, and sales system, adopting an "order-driven + safety stock" business model[86]. - The company’s main products, including multi-bacterial agents and methyl thiophanate, rank among the top in domestic production and sales, with high profit margins in the industry[92]. Shareholder Engagement - The company actively communicates with shareholders, especially small shareholders, to gather their opinions and address their concerns regarding cash dividends[170]. - The company is committed to encouraging participation from small and institutional investors in profit distribution decisions, leveraging professional guidance from intermediaries[170]. - The company has a mechanism in place to deduct cash dividends from shareholders who have illegally occupied company funds[170].

Financial Performance - The company's operating revenue for Q3 2021 reached ¥1,618,552,930.91, representing a year-on-year increase of 72.51%[7] - Net profit attributable to shareholders for the same period was ¥402,519,609.64, a significant increase of 165.72% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥379,495,011.35, up 224.63% year-on-year[7] - Basic earnings per share for Q3 2021 were ¥0.86, reflecting a 160.61% increase from the same period last year[10] - Net profit for the third quarter of 2021 was ¥1,032,880,538.34, compared to ¥435,452,932.40 in the third quarter of 2020, indicating a year-over-year increase of about 137.5%[39] - Operating profit for the third quarter was ¥1,174,198,591.92, up from ¥509,887,689.86 in the same quarter of the previous year, representing a growth of approximately 130.0%[39] - The total comprehensive income for the period reached CNY 1,032,880,538.34, compared to CNY 435,452,932.40 in the same period last year, indicating a significant increase[41] - Basic and diluted earnings per share were both CNY 2.22, up from CNY 0.94 year-over-year[41] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥9,304,726,259.81, a 26.32% increase compared to the end of the previous year[10] - The company's total current assets as of September 30, 2021, amount to 6,849,800,966.08 RMB, an increase from 5,194,663,259.58 RMB at the end of 2020[26] - The total assets of the company as of September 30, 2021, are 9,304,726,259.81 RMB, compared to 7,366,221,966.30 RMB at the end of 2020[29] - The total non-current assets are 2,454,925,293.73 RMB, an increase from 2,171,558,706.72 RMB at the end of 2020[29] - Total liabilities amounted to ¥2,815,636,968.15, up from ¥1,724,039,184.28, reflecting an increase of approximately 63.4%[30] - The total liabilities include accounts payable of 1,386,684,795.30 RMB, up from 1,041,766,697.61 RMB year-over-year[29] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,628,778,851.65, showing a 100.26% increase[10] - Cash inflow from operating activities totaled CNY 4,204,531,465.21, a substantial increase from CNY 1,907,610,530.36 in the previous year[44] - The net cash flow from operating activities was CNY 1,628,778,851.65, compared to CNY 813,349,010.13 in the same period last year[44] - Cash outflow from investment activities amounted to CNY 6,988,146,076.19, compared to CNY 9,687,960,111.54 in the previous year, resulting in a net cash flow from investment activities of -CNY 1,212,855,217.46[44] - The net cash flow from financing activities was -CNY 200,099,128.05, compared to -CNY 150,901,348.78 in the same period last year[44] - The cash and cash equivalents at the end of the period were CNY 1,795,901,679.50, up from CNY 1,369,454,226.18 at the end of the same period last year[46] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,148[20] - The largest shareholder, Anhui Guangxin Group Co., Ltd., holds 175,450,000 shares, accounting for 37.76% of total shares[20] - The company has a total of 8,000,000 shares held by China Industrial Bank Co., Ltd. - Fortune Tianhui Selected Growth Mixed Securities Investment Fund[20] Market and Growth Strategy - The company attributed the increase in revenue and profit to favorable market conditions and rising product prices[16] - The company has plans for market expansion and new product development to sustain growth in the upcoming quarters[16] Research and Development - Research and development expenses for the first three quarters of 2021 were ¥224,187,680.62, compared to ¥138,070,808.34 in the same period of 2020, indicating an increase of about 62.3%[35] Operating Costs - The company reported a total operating cost of ¥3,033,970,025.09 for the first three quarters of 2021, up from ¥2,270,816,711.89 in the same period of 2020, which is an increase of about 33.6%[35]